Sanofi is expanding its presence in Vietnam through a technology-transfer agreement with Vietnam Vaccine Joint Stock Company, known as VNVC. The partnership is designed to bring local production of next-generation vaccines to Vietnam from 2028.
Under the agreement, Sanofi will transfer vaccine manufacturing technology to VNVC. Production will take place at VNVC’s Vaccine and Biological Products Plant in Tay Ninh province. The facility is expected to begin operating by the end of 2027. The first locally produced vaccines are scheduled for 2028, with commercial launches planned from 2029.
The project gives Sanofi a clearer route into local manufacturing rather than relying only on imported finished products. This could reduce supply-chain dependence, improve access to the Vietnamese market and strengthen the company’s position as domestic vaccine demand develops.
VNVC brings an established distribution platform to the partnership. The company operates nearly 300 vaccination centres across Vietnam, giving the future products a ready-made route to market once regulatory approvals and commercial production are in place.
The plant covers more than 26,000 square metres and is supported by an initial investment of more than VND2.5 trillion. It is being built to meet European Union, World Health Organisation and US Food and Drug Administration manufacturing standards.
Planned annual capacity is around 100 million doses. This creates scope to serve domestic demand while also supporting longer-term regional supply ambitions.
Global Opportunities Trust plc LON:GOT) invests globally in undervalued asset classes without reference to the composition of any stock market index.
